AOD-9604 vs Tesamorelin
Where each stands with the FDA, how clinics sell it and what they charge, side by side. This compares what is published about them, not what they might do for you.
AOD-9604
Growth hormone fragment
- FDA standing
- No route for pharmacies to compound it
- Lowest monthly price
- $229/mo at Pepti
- Clinics
- 5
- Sold as
- injection, other
- How it is given
- Subcutaneous injection
- Research in PubMed
- No clinical trial about it among 23 papers; 3 in animals only
Go to clinicLowest per monthAOD-9604 injection (10mg)
Pepti · $229/mo (≈ $245 per 30 days with its fees)
Tesamorelin
Growth hormone-releasing hormone (GHRH) analog
- FDA standing
- A biologic: not for compounding; approved as Egrifta
- Lowest monthly price
- about $123 a month ($230 for 56 days) at Balanced Hormone Health
- Clinics
- 42
- Sold as
- injection, other
- How it is given
- Subcutaneous injection
- Research in PubMed
- 15 clinical trials about it among 107 papers; 3 in animals only
Go to clinicLowest per monthTesamorelin injection (15mg)
Balanced Hormone Health · ≈ $123/mo ($230 for 56 days)
Go to clinicLowest at a clinic we link toTesamorelin injection
Live Vital · from $150/mo (supply not stated, counted as 4 weeks: ≈ $161 per 30 days)
Clinics that sell both
Questions
Can pharmacies compound AOD-9604 and Tesamorelin?
AOD-9604: No route for pharmacies to compound it. Tesamorelin: A biologic: not for compounding. Each compound's page quotes the FDA's own words with the day we read them.
Which costs less, AOD-9604 or Tesamorelin?
By the lowest price that compares per month: AOD-9604 from $229/mo at Pepti, Tesamorelin from about $123 a month ($230 for 56 days) at Balanced Hormone Health. Strengths and amounts differ between clinics, so compare what each price buys.
Which has been studied more in people, AOD-9604 or Tesamorelin?
By PubMed's count of clinical trials about each (the compound in the title): AOD-9604, No clinical trial about it among 23 papers; 3 in animals only; Tesamorelin, 15 clinical trials about it among 107 papers; 3 in animals only. Counted 16 November 2026. A count of trials says nothing about whether either works.